AR and prostate cancer: Moreover, CCND1 is known to further negatively regulate the AR function, not only by directly binding to AR to inhibit transactivation of AR, but also by attenuating AR-induced upregulation of Klk4 in prostate cancer (Knudsen et al., 1999; Comstock et al., 2011).